<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983214</url>
  </required_header>
  <id_info>
    <org_study_id>Cilo-UoI-2016</org_study_id>
    <nct_id>NCT02983214</nct_id>
  </id_info>
  <brief_title>Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?</brief_title>
  <acronym>DORIC</acronym>
  <official_title>Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ioannina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ioannina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the clinical efficacy and safety of dual antiplatelet therapy with
      clopidogrel and cilostazol versus clopidogrel alone in preventing ischemic vascular events in
      patients with type 2 diabetes and symptomatic peripheral arterial disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cilostazol is a quinoline derivative that selectively and reversibly inhibits cellular cyclic
      adenosine monophosphate (cAMP) phosphodiesterase III, thus suppressing cAMP degradation and
      maintaining its high intracellular levels. Through this mechanism, cilostazol inhibits
      platelet aggregation, exerting significant antiplatelet and antithrombotic activity.
      Cilostazol also improves endothelial function and exerts anti-inflammatory, anti-atherogenic
      and vasodilatory effects. Additionally, cilostazol inhibits equilibrative nucleoside
      transporter-1 (ENT-1) which is responsible for the cellular uptake of adenosine, reducing its
      plasma concentration. Through this mechanism, cilostazol maintains high extracellular
      adenosine concentration allowing adenosine to exert its biological effects. Thus, cilostazol
      not only shows potent antithrombotic activity, but also prevents restenosis after
      percutaneous coronary intervention (PCI). Finally, cilostazol has beneficial effects in the
      lipidemic profile reducing triglyceride levels and increasing HDL-cholesterol. Clinical
      studies have shown that in patients with intermittent claudication, cilostazol increases the
      walking distance. Based on these studies, cilostazol administration in combination with an
      antiplatelet drug (clopidogrel or aspirin) is recommended for patients with intertermittent
      claudication.

      Recent pharmacodynamic studies have demonstrated that adding cilostazol to aspirin or
      clopidogrel may represent an effective way to overcome high on-treatment platelet reactivity.
      Additionally, clinical studies have shown that the addition of cilostazol to dual
      antiplatelet therapy with aspirin and clopidogrel (triple antiplatelet therapy, TAPT) in
      patients with acute coronary syndrome undergoing PCI offers significant clinical benefit.
      This favorable effect of cilostazol was confirmed in a recent meta-analysis which included
      nine studies and a total of 2,179 patients undergoing PCI. Furthermore, other clinical
      studies have shown that administration of TAPT with cilostazol reduces restenosis after PCI.
      Finally, the administration of dual antiplatelet therapy with cilostazol and aspirin
      significantly reduces the progression of symptomatic intracranial arterial stenosis compared
      to monotherapy with aspirin.

      The aim of The Diabetic artery Obstruction: is it possible to Reduce Ischemic events with
      Cilostazol? (DORIC) trial is to investigate the clinical efficacy and safety of dual
      antiplatelet therapy (DAPT) with clopidogrel and cilostazol versus clopidogrel alone in
      preventing ischemic vascular eventsin patients with type 2 diabetes (DM2) and symptomatic
      peripheral arterial disease (PAD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who suffer from the primary efficacy end point which is composite of acute ischemic stroke/transient ischemic attack (TIA), myocardial infarction (MI), or death from vascular causes during the entire follow-up period.</measure>
    <time_frame>12 months</time_frame>
    <description>Death from vascular causes: cardiovascular or cerebrovascular</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who suffer from bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria during the entire follow-up period.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants whose major secondary efficacy end point which is the free walking distance or the ankle brachial index (ABI) value will be improved during the entire follow-up period.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who suffer from the secondary safety end points which are palpitations, tachycardia, tachyarrhythmia, hypotension, headache, nausea, diarrhea, blood disorders, drug interruption.</measure>
    <time_frame>12 months</time_frame>
    <description>Blood disorders: thrombocytopenia, leukopenia, agranulocytosis, pancytopenia, aplastic anemia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1885</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Peripheral Artery Disease</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel plus cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75 mg/day plus cilostazol 100 mg twice/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Clopidogrel plus cilostazol</arm_group_label>
    <other_name>Plavix, Clodelib, Clovelen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <arm_group_label>Clopidogrel plus cilostazol</arm_group_label>
    <other_name>Claudiasil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥50 years with DM2 and symptomatic PAD diagnosed clinically (according
             to Fontaine criteria, stage IIa or IIb and III) and by measuring the ΑΒΙ.

        Exclusion Criteria:

          -  Congestive heart failure, history of ventricular tachycardia, ventricular fibrillation
             or multifocal ventricular extrasystoles or QTc prolongation.

          -  Patients with atrial fibrillation taking any anticoagulant therapy or patients with a
             history of cardioembolic ischemic stroke or hemorrhagic stroke.

          -  Patients with a history (≤ 12 months) of acute coronary syndrome receiving dual
             antiplatelet therapy, or patients receiving monotherapy with aspirin.

          -  Patients with hepatic impairment (child-Pugh staging, calibration ≥ 5) or renal
             impairment (creatinine clearance ≤ 30ml / min), recent peptic ulcer, a history of
             hypersensitivity to cilostazol, cancer patients undergoing treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <state>Epirus</state>
        <zip>45110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandros D Tselepis, Professor</last_name>
      <phone>+302651008365</phone>
      <email>atselep@uoi.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Kalantzi KI, Tsoumani ME, Goudevenos IA, Tselepis AD. Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. Expert Rev Clin Pharmacol. 2012 May;5(3):319-36. doi: 10.1586/ecp.12.19. Review.</citation>
    <PMID>22697594</PMID>
  </reference>
  <reference>
    <citation>Dindyal S, Kyriakides C. A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. Recent Pat Cardiovasc Drug Discov. 2009 Jan;4(1):6-14. Review.</citation>
    <PMID>19149700</PMID>
  </reference>
  <reference>
    <citation>Jeong YH, Tantry US, Bliden KP, Gurbel PA. Cilostazol to overcome high on-treatment platelet reactivity in korean patients treated with clopidogrel and calcium-channel blocker. Circ J. 2011;75(11):2534-6. Epub 2011 Oct 5.</citation>
    <PMID>21970840</PMID>
  </reference>
  <reference>
    <citation>Rizzo M, Corrado E, Patti AM, Rini GB, Mikhailidis DP. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother. 2011 Mar;12(4):647-55. doi: 10.1517/14656566.2011.557359. Epub 2011 Feb 2. Review.</citation>
    <PMID>21284580</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol. 2000 Sep;36(3):351-60.</citation>
    <PMID>10975593</PMID>
  </reference>
  <reference>
    <citation>Tselepis AD. Cilostazol-based triple antiplatelet therapy in the era of generic clopidogrel and new potent antiplatelet agents. Curr Med Res Opin. 2014 Jan;30(1):51-4. doi: 10.1185/03007995.2013.850070. Epub 2013 Oct 18.</citation>
    <PMID>24089998</PMID>
  </reference>
  <reference>
    <citation>Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs. 2003;3(2):117-38. Review.</citation>
    <PMID>14727939</PMID>
  </reference>
  <reference>
    <citation>Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian J, Gornik HL, Halperin JL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011 Nov 1;58(19):2020-45. doi: 10.1016/j.jacc.2011.08.023. Epub 2011 Oct 6.</citation>
    <PMID>21963765</PMID>
  </reference>
  <reference>
    <citation>Spiliopoulos S. Antiplatelet therapy in critical limb ischemia: update on clopidogrel and cilostazol. J Cardiovasc Surg (Torino). 2014 Oct;55(5):631-40. Epub 2014 May 28. Review.</citation>
    <PMID>24866775</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Zhang Y, Tang Y, Huang X, Xie Y. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Curr Med Res Opin. 2014 Jan;30(1):37-49. doi: 10.1185/03007995.2013.850067. Epub 2013 Oct 18. Review.</citation>
    <PMID>24083626</PMID>
  </reference>
  <reference>
    <citation>Min PK, Jung JH, Ko YG, Choi D, Jang Y, Shim WH. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. Circ J. 2007 Nov;71(11):1685-90.</citation>
    <PMID>17965485</PMID>
  </reference>
  <reference>
    <citation>Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS; Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005 Nov 1;112(18):2826-32. Epub 2005 Oct 24.</citation>
    <PMID>16246948</PMID>
  </reference>
  <reference>
    <citation>Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005 Apr;36(4):782-6. Epub 2005 Mar 3.</citation>
    <PMID>15746463</PMID>
  </reference>
  <reference>
    <citation>Panagiotakos DB, Georgousopoulou EN, Pitsavos C, Chrysohoou C, Metaxa V, Georgiopoulos GA, Kalogeropoulou K, Tousoulis D, Stefanadis C; ATTICA Study group. Ten-year (2002-2012) cardiovascular disease incidence and all-cause mortality, in urban Greek population: the ATTICA Study. Int J Cardiol. 2015 Feb 1;180:178-84. doi: 10.1016/j.ijcard.2014.11.206. Epub 2014 Nov 26.</citation>
    <PMID>25463360</PMID>
  </reference>
  <reference>
    <citation>Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, Minematsu K, Yamaguchi T; CSPS.com Study Investigators. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. Int J Stroke. 2015 Feb;10(2):253-8. doi: 10.1111/ijs.12420. Epub 2014 Dec 8.</citation>
    <PMID>25487817</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>December 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ioannina</investigator_affiliation>
    <investigator_full_name>Alexandros Tselepis</investigator_full_name>
    <investigator_title>Professor of Biochemistry and Clinical Chemistry</investigator_title>
  </responsible_party>
  <keyword>Cilostazol</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

